This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Enumeral Biomedical Holdings, Inc.
Drug Names(s): PD-1 antagonist, ENUM 388D4, ENUM 244C8
Description: 244C8 is an anti-PD-1 antibody reported to have a distinct epitope binding site from those of first-generation PD-1 antibodies. 244C8 is reported to inhibit PD-1 function without blocking binding of PD-L1 to PD-1.
Enumeral and Pieris
In April 2016, Enumeral Biomedical announced that it has entered into a License and Transfer Agreement (the License Agreement) with Pieris Pharmaceuticals, Inc. and Pieris Pharmaceuticals GmbH (collectively, Pieris).
Pursuant to the terms and conditions of the License Agreement, Pieris is licensing from Enumeral specified intellectual property related to Enumerals anti-PD-1 antibody program ENUM 388D4 for the potential development and commercialization by Pieris of novel multispecific therapeutic proteins comprising fusion proteins based on Pieris Anticalins class of therapeutic proteins and Enumeral antibodies in the field of oncology.
Under the License Agreement, Pieris has agreed to pay Enumeral a $250,000 initial license fee, and Enumeral is providing Pieris with sequence and related information for Enumerals 388D4 family of anti-PD-1 antibodies. The License Agreement provides that Pieris may continue the license by paying Enumeral an...See full deal structure in Biomedtracker
Partners: Pieris AG
Additional information available to subscribers only: